Dosing of CNIs in neonates is particularly challenging due to their unique pharmacokinetics. Neonates have immature liver and kidney functions, which can affect the metabolism and excretion of drugs. Therefore, dosing typically starts at the lower end of the spectrum and is adjusted based on clinical response and serum drug levels. Regular monitoring of blood levels, renal function, and other parameters is essential to ensure safety and efficacy.
